Immunotherapy Combination Boosts PFS for Treatment of High TMB NSCLC – Targeted Oncology
Targeted Oncology |
Immunotherapy Combination Boosts PFS for Treatment of High TMB NSCLC
Targeted Oncology “TMB has emerged as an important biomarker for the activity of immunotherapy. For the first time, this phase III study shows superior PFS with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB,” study … |
